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Abstract SB203580 (4-(4-fluorophenyl)-2-(4-methylsulfinyl-
phenyl)-5-(4-pyridyl)1H-imidazole) is widely used as a specific
inhibitor of p38 mitogen-activated protein kinase (MAPK).
Here, we report that SB203580 activates the serine/threonine
kinase Raf-1 in quiescent smooth muscle cells in a dose-
dependent fashion. The concentrations of SB203580 required
lie above those necessary to inhibit p38 MAPK and we were
unable to detect basal levels of active p38 MAPK. SB203580
does not directly activate Raf-1 in vitro, and fails to activate Ras,
MEK, and ERK in intact cells. In vitro, however, SB203580-
stimulated Raf-1 activates MEK1 in a coupled assay. We
conclude that activation of Raf-1 by SB203580 is not mediated
by an inhibition of p38 MAPK, is Ras-independent, and is
uncoupled from MEK/ERK signaling.
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1. Introduction
Gene expression induced by extracellular factors regulates
cellular functions including di¡erentiation and proliferation.
Signal transduction from the cell surface to the nucleus largely
relies on activation of a family of cytoplasmic protein kinases,
the mitogen-activated protein kinases (MAPKs), that, upon
activation, translocate into the nucleus where they phosphor-
ylate and regulate transcription factors. MAPKs consist of at
least three groups: the extracellular signal-regulated kinases
(ERK1 and ERK2), the N-terminal c-jun kinases (JNKs),
and p38 (reviewed in [1,2]). A widely used strategy to explore
the function of ERK and two members of the p38 group
(p38K and p38L) is the use of speci¢c inhibitors. PD098059
blocks ERK by preventing the activation of its immediate
activator, MEK [3], whereas SB203580 directly inhibits p38K
and p38L but not other p38 MAPKs [4^6]. A prerequisite for
unambiguous interpretations of experiments involving these
inhibitors is the knowledge of possible, additional e¡ects.
For instance, it has recently been suggested that the cyclo-
oxygenase inhibitor indomethacin be used as a control for
PD098059 and SB203580 because both MAPK kinase inhib-
itors also a¡ect Cox1 and Cox2 activities [7].
We started to utilize the SB203580 compound to explore a
role of p38 in PDGF-BB signaling in baboon smooth muscle
cells. Here, we report the unexpected ¢nding that SB203580
strongly activates the serine/threonine kinase Raf-1. Raf-1 ac-
tivation by growth factors is a complex process (reviewed in
[8,9]). In quiescent cells, Raf-1 is located in the cytoplasm and
is kept inactive by binding to 14-3-3 proteins. Activated,
GTP-bound Ras binds to the RBD (Ras-binding domain)
located in the N-terminus of Raf-1, thereby displacing
14-3-3 proteins [10,11] and translocating Raf-1 to the plasma
membrane [12,13]. The molecular basis for activation of Raf-1
at the plasma membrane remains to be elucidated. It may
include tyrosine phosphorylation and binding of phospholip-
ids (reviewed in [8,9]).
Active Raf-1 phosphorylates MEK at two adjacent serine
residues. This results in an activation of MEK that, in turn,
phosphorylates and activates ERK.
In this study, we present evidence that SB203580 activates
Raf-1 in a Ras-independent fashion and that SB203580-stimu-
lated Raf phosphorylates MEK in vitro but not in intact cells.
2. Materials and methods
2.1. Materials
Monoclonal antibodies against MEK1 and Ras were purchased
from Transduction Laboratories (Lexington, KY), polyclonal Raf-1
antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA),
and phospho-ERK speci¢c antibodies from New England Biolabs Inc.
(Beverly, MA). Tissue culture media and fetal calf serum were from
Gibco-BRL (Gaithersburg, MD). SB203580 and SB202474 were from
Calbiochem (La Jolla, CA). Protein A agarose was from Boehringer
Mannheim (Indianapolis, IN) and [Q-32P]ATP from Du Pont-New
England Nuclear (Boston, MA). PDGF-BB was a kind gift from
Zymogenetics (Seattle, WA). Catalytically inactive ERK2 (K52R)
and MEK1 (K97M), and GST-RBD beads were prepared with minor
modi¢cations as described [14^16]. The ECL kit was purchased from
Amersham (Arlington Heights, IL).
Bu¡er HEB: 25 mM HEPES-NaOH, pH 7.5, 10% glycerol, 5 mM
EDTA, 5 mM EGTA, 150 mM NaCl, 100 mM Na-pyrophosphate, 50
mM NaF, 1 mM Na-vanadate, 1 mM benzamidine, 0.1% 2-mercap-
toethanol, 1% Triton X-100, 1 WM pepstatin A, 2 Wg/ml leupeptin and
20 kallikrein inhibitor units/ml aprotinin; bu¡er MLB: 25 mM
HEPES-NaOH, pH 7.5, 150 mM NaCl, 1% Triton X-100, 10% glyc-
erol, 10 mM MgCl2, 1 mM EDTA, 1 mM Na-vanadate, 25 mM NaF,
0.1% 2-mercaptoethanol, 1 WM pepstatin A, 2 Wg/ml leupeptin and 20
kallikrein inhibitor units/ml aprotinin; kinase bu¡er: 20 mM HEPES-
NaOH, pH 7.5, 20 mM MgCl2, 0.1% 2-mercaptoethanol; TTBS: 25
mM Tris-HCl, pH 7.5, 500 mM NaCl, 0.1% Triton X-100, 0.1%
2-mercaptoethanol.
2.2. Smooth muscle cell (SMC) culture and extraction
Baboon aortic SMCs were prepared as described previously [17].
Cells were grown in Dulbecco’s modi¢ed Eagle’s medium supple-
mented with 10% fetal calf serum, 200 U/ml penicillin and 0.2 mg/
ml streptomycin. SMCs were starved in serum-free medium for 2^3
days. After stimulation as indicated, cells were washed twice with
phosphate-bu¡ered saline and lysed in 1 ml/10 cm plate HEB (for
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kinase assays) and MLB (for ras assays). Lysates were incubated for
20 min on ice and cleared by centrifugation in a microfuge for 10 min
at 10 000Ug. When SB203580 was used, controls contained the same
concentrations of DMSO (90.25%).
2.3. Kinase assays
For Raf-1 and MEK1 assays, 1 Wg of antibody and 20 Wl of protein
A agarose slurry (1 mg/ml protein A) were added to 1 ml of extract
containing approximately 500 Wg protein. The samples were stirred
overnight at 4‡C. The beads were washed in bu¡er HEB followed by
kinase bu¡er. Kinase reaction was performed on the beads in kinase
bu¡er containing 1 Wg of protein substrate and 0.1 mM ATP (5000
cpm/pmol). The assay mix was incubated for 30 min at 30‡C. The
reaction was terminated by adding 10 Wl 4ULaemmli bu¡er. The
samples were subjected to SDS-PAGE. The gels were stained with
Coomassie blue to monitor equal loading, dried, and the extent of
substrate phosphorylation was determined by phosphorimaging (fa-
cility at the Fred Hutchinson Cancer Research Center, Seattle, WA)
or densitometric analysis of autoradiographs.
ERK activities were analyzed by determining the phosphorylation
status of ERK1 and ERK2. 20 Wl of extract was subjected to SDS-
PAGE followed by Western blotting. The blots were incubated with
phospho-ERK speci¢c antibodies (1:1000) and the bands visualized
by ECL using a protocol supplied by the manufacturer.
2.4. Ras assay
Twenty micoliters of packed GST-RBD beads were added to 1 ml
cell extract. The mixture was incubated on a rocker for 30 min at 4‡C.
The beads were washed three times with 1 ml MLB before being
subjected to SDS-PAGE. The a⁄nity-precipitated Ras protein was
visualized by Western blotting using a Ras antibody (0.5 Wg/ml) and
an ECL kit.
3. Results and discussion
3.1. SB203580 activates Raf-1
The treatment of quiescent SMCs with the p38 MAPK in-
hibitor, SB203580, results in a dose- and time-dependent acti-
vation of Raf-1 (Fig. 1). SB203580 only activates Raf-1 when
added to intact cells. When cell lysates of quiescent cells were
incubated with SB203580 before and during the immunopre-
cipitation, Raf-1 remained inactive. It is also important to
note that an inactive derivative of the p38 MAPK inhibitor,
SB202474 (25 WM), had no e¡ect on Raf-1 activity (not
shown).
Raf-1 was inactive in quiescent cells and became stimulated
more than 100-fold in the presence of 8^25 WM SB203580
(Fig. 1). When the extents of Raf-1 activation induced by
PDGF-BB and SB203580 were compared, 25 WM SB203580
was 30 times stronger than 10 ng/ml PDGF-BB which induced
the same level of Raf-1 activity as 0.8 WM SB203580. In two
independent experiments, 1 h incubation of 8 WM SB203580
activated Raf-1 approximately 30-fold in NIH 3T3 mouse
¢broblasts demonstrating that this e¡ect of the p38 MAPK
inhibitor is not limited to SMCs (not shown).
The obvious question was whether the SB203580-induced
activation of Raf-1 is mediated by an inhibition of p38
MAPK. We have recently reported that, in baboon SMCs,
MAPKAP kinase-2 activation by pervanadate is completely
abolished in the presence of 0.8 WM SB203580 [18]. This ob-
servation is consistent with published IC50 values for the
SB203580 sensitive p38 MAPK isoforms, p38K and p38L
[5,6]. Raf-1 activation by SB203580, however, did not reach
a maximum at concentrations of SB203580 as high as 25 WM
(Fig. 1). These data suggest to us that inhibition of p38
MAPK is probably not responsible for the stimulation of
Raf-1 by SB203580. In addition, we did not detect signi¢cant
levels of p38K or p38L activities in quiescent cells using either
an immunoprecipitation assay with ATF-2 as substrate, or an
immunodetection assay with an antibody speci¢c for the
phosphorylated form of p38 MAPK; both assays gave pos-
itive results when SMCs were stimulated with pervanadate
(not shown). In the light of the recent observation that
SB203580 blocks cyclooxygenases (Cox1 and Cox2 [7]), we
tested whether the general Cox inhibitor, indomethacin, can
mimic the activatory e¡ect of SB203580 on Raf-1. The result
was negative; indomethacin in concentrations up to 10 WM
had no e¡ect on Raf-1 activity (not shown; 1^10 WM indo-
methacin is typically used to block cyclooxygenases).
Time course experiments demonstrated that a 10 min incu-
bation with SB203580 was su⁄cient to elicit approximately
25% of the maximal response that was measured at 60 min;
after that time point, kinase activity declined (Fig. 2).
3.2. SB203580 does not stimulate Ras, MEK, or ERK
To investigate whether SB203580 mediates Raf activation
by activating Ras, we treated quiescent SMCs with 25 WM
FEBS 21510 6-2-99
Fig. 1. Dose-dependent activation of Raf-1 by SB203580. Quiescent
SMCs were stimulated for 30 min with di¡erent doses of SB203580
and 25 WM SB202474, and for 15 min with 10 ng/ml PDGF-BB, re-
spectively. Raf-1 activity was determined as described in Section 2.
The upper panel shows an autoradiograph of a representative ex-
periment; the arrow indicates position of substrate. Lower panel:
Relative kinase activities were calculated as percent of the highest
activity obtained (at 25 WM SB203580). All data points are
mean þ S.D. of three independent experiments.
Fig. 2. Time course of Raf-1 activity induced by SB203580. Quies-
cent SMCs were stimulated with 25 WM SB203580 for di¡erent time
points. Raf-1 activity was measured as described in Section 2. Ki-
nase activities are presented as percent of the highest activity ob-
tained (at 60 min). All data points are mean þ S.D. of three inde-
pendent experiments.
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SB203580 and determined the amount of GTP-bound Ras at
di¡erent time points. Controls were stimulated with PDGF-
BB for 10 min. Whereas the growth factor induced Ras acti-
vation, SB203580 failed to signi¢cantly increase the level of
GTP-bound Ras (Fig. 3A). It is therefore unlikely that acti-
vation of Ras is required for SB203580 to stimulate Raf-1.
Similar results were obtained when we measured the activity
of the Raf substrate MEK1 following incubation of SMCs
with SB203580 and PDGF-BB, respectively. Whereas MEK1
was strongly activated by PDGF-BB, SB203580 failed to elicit
a similar response; typically, a slight activation (1.5-fold) of
MEK1 was observed by SB203580 (Fig. 3B). When the
MEK1 substrates, ERK1 and ERK2, were measured, only
PDGF-BB was stimulatory; 25 WM SB203580 rather de-
creased basal ERK activities (Fig. 3C). These data indicate
that SB203580-induced Raf is not capable of engaging
MEK/ERK signaling in intact cells. To rule out the possibility
that SB203580-activated Raf-1 phosphorylated the recombi-
nant MEK1 in vitro on sites other than those required for
MEK activation, we performed a coupled assay. Immunopre-
cipitates of SB203580-activated Raf-1 were mixed with
MEK-1 immunoprecipitates from quiescent SMCs, and phos-
phorylation of ERK was determined. Only assays containing
both SB203580-stimulated Raf and MEK1 showed ERK
phosphorylation; when Raf was immunoprecipitated from
DMSO-treated cells, or in the absence of MEK, no ERK
phosphorylation was measured (Fig. 4).
3.3. Summary and conclusions
The mechanism of how SB203580 activates Raf-1 remains
unclear: we suggest that this process is independent of an
inhibition of p38 or cyclooxygenases, both targets for
SB203580 [5^7]. At this point, we cannot distinguish between
the two possibilities of SB203580 action: an inhibition of a
Raf suppressor, or a stimulation of a Raf activator.
An interesting observation is that SB203580-activated Raf-1
failed to activate MEK in intact cells although it phosphor-
ylates and activates MEK1 immunoprecipitated from the
same cells in vitro.
This di¡erence could be explained by an inhibitory e¡ect of
SB203580 on MEK1 in vivo. Such a mechanism may be re-
sponsible for the recently observed inhibition of ERK by
SB203580 following arsenite treatment [19]. However, we
have recently shown in pervanadate-stimulated SMCs that
SB203580 prolongs the activation of MEK1 [18].
Alternatively, in intact cells, additional proteins may be
required for the activation of MEK1 by Raf. Those may in-
clude additional MEK kinases or sca¡old proteins. Examples
for both have recently been described [20,21]. In in vitro as-
says, such requirements may be overcome by high substrate
concentrations.
Our data suggest the possibility that e¡ects of SB203580
that were attributed to p38 inhibition may, in part, be due
to the activation of Raf-1. This is particularly interesting re-
garding recent reports that SB203580, and structurally related
p38 MAPK inhibitors, can prevent apoptosis in certain cell
systems [22^24] because Raf-1 has also been suggested in sev-
eral studies to exert anti-apoptotic e¡ects [25^27].
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